JPMorgan analyst John Stansel upgraded Alignment Healthcare (ALHC) to Overweight from Neutral with a price target of $20, up from $18, after assuming coverage of the name. The firm believes the company is positioned to be one of the “cleaner ways” to play Medicare Advantage into 2026. Alignment is continuing to gain share as its “differentiated” approach to care, stratification, and engagement supports recent cohort improvement, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare’s Promising Growth Trajectory and Strategic Expansion: A Buy Recommendation by John Stansel
- Alignment Healthcare management to meet with KeyBanc
- Alignment Healthcare price target raised to $18 from $17 at JPMorgan
- Alignment Healthcare price target raised to $18.50 from $17 at TD Cowen
- Alignment Healthcare’s Earnings Call Highlights Strong Growth